| REVIEW ARTICLE |
|
| Year : 2021 | Volume
: 16
| Issue : 5 | Page : 20-28 |
|
|
Spectrum of interstitial lung disease in rheumatic diseases
Gouri Koduri1, Damodar Makkuni2, Ameen Jubber3, Arumugam Moorthy4
1 Department of Rheumatology, Southend University Hospital, Westcliff on Sea, UK
2 Department of Rheumatology, James Paget Hospital NHS Trust, Norfolk, UK
3 Department of Rheumatology, Leicester University Hospital NHS Trust UK, Leicester, UK
4 Department of Life Sciences, Leicester Medical School, University of Leicester, Leicester, UK
Correspondence Address:
Dr. Gouri Koduri
Department of Rheumatology, Southend University Hospital NHS Trust, Prittlewell Chase, Westcliff on Sea
UK
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0973-3698.332975
|
|
|
Among the diverse forms of lung involvement, interstitial lung disease (ILD) and pulmonary arterial hypertension are two important conditions in patients with rheumatic diseases that are associated with significant morbidity and mortality. The management of ILD is challenging and these challenges are associated with several mechanisms, particularly the inflammatory processes of immune cells and also fibrotic processes, which play a crucial role in disease progression, making immunosuppressive therapy less effective. However, recent advances in pharmacologic interventions have been shown to delay disease progression of these lung conditions and improve patient survival. Disease stratification and early identification of patients who are more likely to progress, and thus in need of more aggressive treatment, is important in the field of ILD. Early diagnosis, monitoring, and multidisciplinary team input are very important to improve overall outcomes. This review focuses on ILD in patients with various rheumatic diseases (rheumatoid arthritis, myositis, Sjogren' syndrome, and systemic sclerosis) and the challenges.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
